SC 13G/A | 2021-02-08 | Novartis Institutes for BioMedical Research, Inc. | Surface Oncology, Inc. | 3,948,482 | 9.7% | EDGAR |
SC 13G/A | 2021-02-02 | Atlas Venture Fund IX, L.P. | Surface Oncology, Inc. | 2,945,453 | 7.2% | EDGAR |
SC 13G | 2020-12-10 | FMR LLC | Surface Oncology, Inc. | 2,048,321 | 5.0% | EDGAR |
SC 13G | 2020-05-29 | BIOTECHNOLOGY VALUE FUND L P | Surface Oncology, Inc. | 1,112,895 | 3.1% | EDGAR |
SC 13G | 2020-05-29 | EcoR1 Capital, LLC | Surface Oncology, Inc. | 5,033,861 | 12.8% | EDGAR |
SC 13G | 2020-05-29 | Venrock Healthcare Capital Partners II, L.P. | Surface Oncology, Inc. | 3,877,895 | 9.9% | EDGAR |
SC 13G/A | 2020-02-14 | EcoR1 Capital, LLC | Surface Oncology, Inc. | 1,301,713 | 4.7% | EDGAR |
SC 13G/A | 2020-02-13 | New Enterprise Associates 14, L.P. | Surface Oncology, Inc. | 3,312,877 | 11.9% | EDGAR |
SC 13G/A | 2020-02-13 | Lilly Ventures Fund I LLC | Surface Oncology, Inc. | 3,447,817 | 12.4% | EDGAR |
SC 13G/A | 2020-02-07 | FMR LLC | Surface Oncology, Inc. | 1,298,283 | 4.7% | EDGAR |
SC 13G/A | 2020-02-04 | Atlas Venture Fund IX, L.P. | Surface Oncology, Inc. | 4,654,453 | 16.7% | EDGAR |
SC 13G/A | 2019-02-14 | EcoR1 Capital, LLC | Surface Oncology, Inc. | 2,261,328 | 8.2% | EDGAR |
SC 13G/A | 2019-02-14 | EcoR1 Capital, LLC | Surface Oncology, Inc. | 2,261,328 | 8.2% | EDGAR |
SC 13G | 2019-02-14 | Lilly Ventures Fund I LLC | Surface Oncology, Inc. | 3,447,817 | 12.5% | EDGAR |
SC 13G/A | 2019-02-13 | FMR LLC | Surface Oncology, Inc. | 1,692,661 | 6.1% | EDGAR |
SC 13G | 2019-02-13 | New Enterprise Associates 14, L.P. | Surface Oncology, Inc. | 3,312,877 | 12.0% | EDGAR |
SC 13G | 2019-02-08 | Atlas Venture Fund IX, L.P. | Surface Oncology, Inc. | 4,654,453 | 16.8% | EDGAR |
SC 13G/A | 2018-12-20 | FMR LLC | Surface Oncology, Inc. | 1,752,984 | 6.3% | EDGAR |
SC 13G | 2018-11-13 | EcoR1 Capital, LLC | Surface Oncology, Inc. | 1,747,657 | 6.3% | EDGAR |
SC 13G | 2018-04-25 | FMR LLC | Surface Oncology, Inc. | 3,138,986 | 11.4% | EDGAR |